Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024

Date: June 24, 2019
Pages: 117
Price:
US$ 5,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HEF686577EAEN
Leaflet:

Download PDF Leaflet

Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024
“Hemato oncology testing market to register a CAGR of 14.8% from 2019 to 2024”

The hemato oncology testing market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8% during the forecast period. Growth in this market is mainly driven by the rising incidences & prevalence of leukemia, increasing collaborations for developing new assay kits, and the growing focus on personalized medicine.

“Services accounted for the larger share of the hemato oncology testing market in 2018”

Based on product & service, the market is segmented into assay kits and services. In 2018, the services segment accounted for a larger share of this market majorly due to the high prevalence of leukemia & lymphoma. The market is set to grow on account of increasing collaborations between hemato oncology testing product manufacturers and pharmaceutical companies.

“Leukemia accounted for the largest share of the hemato oncology testing market in 2018”

Based on cancer type, the hemato oncology testing market has been segmented into three types— leukemia, lymphoma, and other cancers. Leukemia accounted for the largest share in 2018 and is anticipated to witness the highest growth rate during the forecast period due to the need for continuous monitoring of leukemia patients. In addition, increasing awareness about checking the status of minimal residual disease (MRD) in leukemia patients is another factor supporting market growth.

“North America dominates the hemato oncology testing market”

North America, which includes the US and Canada, accounted for the largest share of the hemato oncology testing in 2018. The large share of this market segment can be attributed to the availability of reimbursement for hemato oncology testing products, increasing awareness regarding advanced treatment theories, and the strong presence of industry players in the region.

Breakdown of supply-side primary interviews, by company type, designation, and region:
  • By Company Type: Tier 1: 70% , Tier 2: 20%, and Tier 3: 10%
  • By Designation: C-level: 30%, Director-level: 20%, and Others: 50%
  • By Region: North America: 35%, Europe: 24%, Asia: 25%, and the RoW: 16%
The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).

Research Coverage

This report studies the hemato oncology testing market based on product & service, cancer type, technology, end user, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro-markets with respect to their growth trends, prospects, and contributions to the total hemato oncology testing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on the hemato oncology testing offered by the top 12 players in the market. The report analyzes the hemato oncology testing market by product and region
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various hemato oncology testing across key geographic regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the hemato oncology testing market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the hemato oncology testing market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
  1.2.1 MARKETS COVERED
  1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 SECONDARY DATA
  2.1.1 KEY DATA FROM SECONDARY SOURCES
2.2 PRIMARY DATA
  2.2.1 KEY DATA FROM PRIMARY SOURCES
2.3 MARKET SIZE ESTIMATION
  2.3.1 BOTTOM-UP APPROACH
  2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 HEMATO-ONCOLOGY TESTING: MARKET OVERVIEW
4.2 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT AND SERVICE (2018)
4.3 GEOGRAPHICAL SNAPSHOT OF THE HEMATO-ONCOLOGY TESTING MARKET

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 DRIVERS
    5.2.1.1 Increasing incidence of hematologic cancer
    5.2.1.2 Increasing collaborations
    5.2.1.3 Increasing conferences on personalized medicine
  5.2.2 OPPORTUNITIES
    5.2.2.1 Drug diagnostics co-development
    5.2.2.2 Emerging markets
  5.2.3 RESTRAINTS
    5.2.3.1 Uncertain reimbursement scenario in different regions
    5.2.3.2 Complex regulatory frameworks delaying the approval of new molecular diagnostic tests
  5.2.4 CHALLENGES
    5.2.4.1 Intellectual property rights protection issues

6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE

6.1 INTRODUCTION
6.2 SERVICES
  6.2.1 RISING INCIDENCE OF HEMATOLOGIC CANCER TO INCREASE THE DEMAND FOR HEMATO-ONCOLOGY SERVICES
6.3 ASSAY KITS
  6.3.1 GROWING FOCUS ON THE DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE THE GROWTH OF THIS MARKET SEGMENT

7 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE

7.1 INTRODUCTION
7.2 LEUKEMIA
  7.2.1 ACUTE MYELOID LEUKEMIA
    7.2.1.1 AML IS THE MOST COMMON ACUTE LEUKEMIA AFFECTING ADULTS
  7.2.2 ACUTE LYMPHOCYTIC LEUKEMIA
    7.2.2.1 North America accounted for the largest share of the ALL segment
  7.2.3 OTHER LEUKEMIAS
7.3 LYMPHOMA
  7.3.1 NON-HODGKIN LYMPHOMA
    7.3.1.1 Non-Hodgkin lymphoma holds the largest share of the market for lymphoma
  7.3.2 HODGKIN LYMPHOMA
    7.3.2.1 APAC hemato-oncology testing market for Hodgkin lymphoma will grow at the highest rate
7.4 OTHER CANCERS

8 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY

8.1 INTRODUCTION
8.2 PCR
  8.2.1 PCR ACCOUNTED FOR THE LARGEST SHARE OF THE HEMATO-ONCOLOGY TESTING MARKET IN 2018
8.3 IHC
  8.3.1 IHC ACCOUNTED FOR THE SECOND-LARGEST SHARE OF THE HEMATO-ONCOLOGY TESTING MARKET
8.4 NGS
  8.4.1 NGS IS EXPECTED TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
8.5 CYTOGENETICS
  8.5.1 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE CYTOGENETICS MARKET
8.6 OTHER TECHNOLOGIES

9 HEMATO-ONCOLOGY TESTING MARKET, BY END USER

9.1 INTRODUCTION
9.2 CLINICAL LABORATORIES
  9.2.1 PRESENCE OF ROBUST INFRASTRUCTURE IS THE MAJOR DRIVING FACTOR FOR THIS SEGMENT
9.3 HOSPITALS
  9.3.1 HOSPITALS ACCOUNTED FOR THE SECOND-LARGEST SHARE OF THE MARKET, BY END USER
9.4 ACADEMIC & RESEARCH INSTITUTES
  9.4.1 APAC MARKET FOR ACADEMIC & RESEARCH INSTITUTES WILL GROW AT THE HIGHEST RATE
9.5 OTHER END USERS

10 HEMATO-ONCOLOGY TESTING MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
  10.2.1 US
    10.2.1.1 The US dominates the North American hemato-oncology testing market
  10.2.2 CANADA
    10.2.2.1 Initiatives undertaken by healthcare authorities in the country to ensure the delivery of better public healthcare to support the growth of the hemato-oncology testing market in Canada
10.3 EUROPE
  10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET GROWTH
10.4 ASIA PACIFIC
  10.4.1 ASIA PACIFIC MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
10.5 REST OF THE WORLD

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 MARKET RANKING ANALYSIS, 2017
11.3 KEY STRATEGIES
  11.3.1 PRODUCT LAUNCHES & APPROVALS, 2016–2019
  11.3.2 EXPANSIONS, 2016–2019
  11.3.3 PARTNERSHIPS AND COLLABORATIONS, 2016–2019
  11.3.4 ACQUISITIONS, 2016–2019

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 F. HOFFMAN-LA ROCHE LTD.
12.2 ABBOTT LABORATORIES
12.3 QIAGEN N.V.
12.4 THERMO FISHER SCIENTIFIC, INC.
12.5 ILLUMINA, INC.
12.6 BIO-RAD LABORATORIES, INC.
12.7 MOLECULARMD (SUBSIDIARY OF ICON PLC)
12.8 ARCHERDX, INC.
12.9 ARUP LABORATORIES INC.
12.10 ASURAGEN, INC.
12.11 INVIVOSCRIBE, INC.
12.12 ADAPTIVE BIOTECHNOLOGIES.
*Details on Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS

LIST OF TABLES

TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2018–2040
TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030
TABLE 3 HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2009 VS. 2016
TABLE 4 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030
TABLE 5 REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS
TABLE 6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 7 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 8 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 9 HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 11 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 12 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 13 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 14 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 15 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2017–2024 (USD MILLION)
TABLE 16 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION, 2017–2024 (USD MILLION)
TABLE 17 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 18 HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2017–2024 (USD MILLION)
TABLE 19 HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2017–2024 (USD MILLION)
TABLE 20 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 21 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 22 HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION, 2017–2024 (USD MILLION)
TABLE 23 HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION, 2017–2024 (USD MILLION)
TABLE 24 HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION, 2017–2024 (USD MILLION)
TABLE 25 HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION, 2017–2024 (USD MILLION)
TABLE 26 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 27 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 28 HEMATO-ONCOLOGY TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 29 HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION, 2017–2024 (USD MILLION)
TABLE 30 HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2017–2024 (USD MILLION)
TABLE 31 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 32 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 33 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 34 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 35 NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 36 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 38 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 39 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 40 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 41 US: LEUKEMIA AT A GLANCE
TABLE 42 US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 43 US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 44 US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 45 US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 46 US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 47 US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 48 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 49 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 50 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 51 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 52 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 53 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 54 INCIDENCE OF LEUKEMIA, BY COUNTRY, 2018–2035
TABLE 55 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 56 EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 57 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 58 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 59 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 60 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 61 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 62 GERIATRIC POPULATION, BY COUNTRY, 2015 VS. 2030
TABLE 63 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 64 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 65 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 66 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 67 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 68 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 69 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 70 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 71 ROW: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 72 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 73 ROW: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 74 ROW: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION)
TABLE 75 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 76 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 77 RANKING OF COMPANIES IN THE HEMATO-ONCOLOGY TESTING MARKET, 2018

LIST OF FIGURES

FIGURE 1 HEMATO-ONCOLOGY TESTING MARKET
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH
FIGURE 5 HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT AND SERVICE, 2019 VS. 2024 (USD MILLION)
FIGURE 8 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 9 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
FIGURE 10 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2019 VS. 2024 (USD MILLION)
FIGURE 11 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2019 VS. 2024 (USD MILLION)
FIGURE 12 INCREASING INCIDENCE OF HEMATOLOGY CANCER TO DRIVE MARKET GROWTH
FIGURE 13 SERVICES TO DOMINATE THE NORTH AMERICAN MARKET IN 2018
FIGURE 14 NORTH AMERICA ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2018
FIGURE 15 HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
FIGURE 16 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2019 VS. 2024)
FIGURE 17 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE (2019 VS. 2024)
FIGURE 18 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY (2019 VS. 2024)
FIGURE 19 HEMATO-ONCOLOGY TESTING MARKET, BY END USER (2019 VS. 2024)
FIGURE 20 HEMATO-ONCOLOGY TESTING MARKET, BY REGION (2019 VS. 2024)
FIGURE 21 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
FIGURE 22 KEY DEVELOPMENTS IN THE HEMATO-ONCOLOGY TESTING MARKET FROM

2016 TO 2018

FIGURE 23 ROCHE DIAGNOSTIC: COMPANY SNAPSHOT (2018)
FIGURE 24 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2018)
FIGURE 25 QIAGEN N.V.: COMPANY SNAPSHOT (2018)
FIGURE 26 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
FIGURE 27 ILLUMINA, INC.: COMPANY SNAPSHOT (2018)
FIGURE 28 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2018)
FIGURE 29 ICON PLC: COMPANY SNAPSHOT (2018)
Skip to top


Ask Your Question

Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: